

2018 から 2020 年の実績

原著 :

英文

1. Ito S, Kobayashi D, Hasegawa E, Takai C, Nemoto T, Lee H, Abe A, Otani H, Ishikawa H, Murasawa A, Narita I, Nakazono K. An analysis of the biological disease-modifying antirheumatic drug-free condition of adalimumab-treated rheumatoid arthritis patients. *Intern Med* 58 (4) 511–519, 2019 doi: 10.2169/internalmedicine.1332-18.
2. Okura C, Ishikawa H, Abe A, Yonemoto Y, Okamura K, Suto T, Oyakawa T, Miyagawa Y, Otani H, Ito S, Kobayashi D, Nakazono K, Murasawa A, Takagishi K, Chikuda H. Long-term patient reported outcomes of elbow, wrist and hand surgery for rheumatoid arthritis. *Int J Rheum Dis*. 21(9):1701-1708, doi: 10.1111/1756-185X.13340. [Epub ahead of print]
3. Nagasaka K, Harigai M, Hagino N, Hara A, Horita T, Hayashi T, Itabashi M, Ito S, Katsumata Y, Kawashima S, Naniwa T, Sada KE, Nango E, Nakayama T, Tsutsumino M, Yamagata K, Homma S, Arimura Y. Systematic Review and Meta-analysis for 2017 Clinical Practice Guidelines of the Japan Research Committee of the Ministry of Health, Labour, and Welfare for Intractable Vasculitis for the Management of ANCA-associated Vasculitis. *Mod Rheumatol*. 2018 Jul 12:1-31. doi: 10.1080/14397595.2018.1500111. [Epub ahead of print]
4. Furukawa H, Oka S, Shimada K, Hashimoto A, Komiya A, Tsunoda S, Suda A, Ito S, Saisho K, Katayama M, Shinohara S, Sato T, Nagatani K, Minota S, Matsui T, Fukui N, Sugii S, Sano H, Migita K, Nagaoka S, Tohma S. Independent association of HLA-DPB1*02:01 with rheumatoid arthritis in Japanese populations. *PLOS ONE*. 2018 Sep 20;13(9):e0204459. doi: 10.1371/journal.pone.0204459. eCollection 2018.
5. Takada K, Katada Y, Ito S, Hayashi T, Kishi J, Itoh K, Yamashita H, Hirakata M, Kawahata K, Kawakami A, Watanabe N, Atsumi T, Takasaki Y, Miyasaka N. Impact of adding tacrolimus to initial treatment of interstitial pneumonitis in polymyositis/dermatomyositis: a single-arm clinical trial. *Rheumatology* doi:10.1093/rheumatology/kez394 2019
6. Yamashita M, Kobayashi T, Ito S, Kaneko C, Murasawa A, Hajime Ishikawa H, Tabeta K. The periodontal inflamed surface area is associated with the clinical response to biological disease-modifying antirheumatic

drugs in rheumatoid arthritis: A retrospective study. *Mod Rheumatol* DOI: 10.1080/14397595.2019.1680100

7. Hasegawa E, Kobayashi D, Kurosawa Y, Taniguchi S, Otani H, Abe A, Ito S, Nakazono K, Murasawa A, Narita I, Ishikawa I. Nutritional status as the risk factor of serious infection in patients with rheumatoid arthritis. *Mod Rheumatol*, DOI: 10.1080/14397595.2019.1681653
8. Lee H, Ishikawa H, Shibuya T, Takai T, Nomura Y, Kobayashi D, Abe A, Otani H, Ito S, Nakazono K, Ryu K, Ishii T, Saito S, Abe K, Murasawa A. Changes in radiographic findings and plantar pressure distribution following forefoot reconstructive surgery for patients with rheumatoid arthritis. *Mod Rheumatol*, DOI: 10.1080/14397595.2019.1680094
9. Asano R, Ito S, Kobayashi D, Hasegawa E, Higashitani K, Nakazono K, Murasawa A, Narita I, Taki H, Tobe K, Ishikawa H. Efficacy and safety of alogliptin for glucocorticoid-induced hyperglycemia in patients with autoimmune-diseases: A Retrospective Analysis. *Clin Rheumatol Rel Res* 32 (1) 35–47, 2020
10. Takai C, Ito S, Kobayashi D, Nemoto T, Lee H, Abe A, Otani H, Nakazono K, Murasawa A, Ishikawa H. Two-year outcomes of infliximab discontinuation in patients with rheumatoid arthritis: A retrospective analysis from a single center. *Intern Med* 59 (16) 1963–1970, 2020
11. Nomura Y, Ishikawa H, Abe A, Otani H, Ito S, Nakazono K, Murasawa A. Arthrodesis of the digital joint using intraosseus wiring in patients with rheumatoid arthritis. *Mod Rheumatol* DOI: 10.1080/14397595.2020.1726607.
12. Matsuoka H, Kabata D, Taura A, Matsui T, Takahi K, Hirano F, MKatayama M, Okamoto A, Suenaga Y, Suematsu E, Yoshizawa S, Ohmura K, Ito S, Takaoka H, Oguro E, Kuzuya K, Okita Y, Udagawa C, Yoshimura M, Teshigawara S, Harada Y, Isoda K, Yoshida Y, Ohshima S, Tohma S, Saeki Y. Lack of association between a disease-susceptible single-nucleotide polymorphism, rs2230926 of TNFAIP3, and tumour necrosis factor inhibitor therapeutic failure in Japanese patients with rheumatoid arthritis. *Scand J Rheumatol* 49:253–255, 2020
13. Okabayashi R, Ishikawa H, Abe A, Otani H, Funamura K, Kakutani R, Ito S, Kurosawa Y, Sakai S, Nakazono K, Suzuki M, Matsuyama Y, Murasawa A. Twenty years' follow up of radiocarpal arthrodesis for rheumatoid wrists. *Mod Rheumatol* DOI: 10.1080/14397595.2020.1782565

14. Sato H, Takai C, Kazama JJ, Wakamats A, Hasegawa E, Kobayashi D, Kondo N, Nakatsue T, Abe A, Ito S, Ishikawa H, Kuroda T, Suzuki Y, Narita I. Serum hepcidin level, iron metabolism and osteoporosis in patients with rheumatoid arthritis. *Sci Rep* 2020 Jun 18;10(1):9882. doi: 10.1038/s41598-020-66945-3.
15. Sato H, Takai, KondoN, Kurosawa Y, Hasegawa E, Wakamatsu A, Kobayashi D, Nakatsue T, Abe A, Ito S, Ishikawa H, Kazama JJ, Kuroda T, Suzuki Y, Endo N, Narita I. Cumulative incidence of femoral localized periosteal thickening (beaking) preceding atypical femoral fractures in patients with rheumatoid arthritis. *Osteoporosis International*. <https://doi.org/10.1007/s00198-020-05601-y>
16. Ito S, SakaiS, Kurosawa Y, Kobayashi D, Okabayashi R, Abe A, Otani H, Nakazono K, Murasawa A, Narita I, Ishikawa H. The long-term observation of patients with rheumatoid arthritis who achieved a biological disease-modifying antirheumatic drug-free condition with adalimumab. *Mod Rheumatol*. doi: 10.1080/14397595.2020.1823551
17. Okita S, Isikawa H, Abe A, Ito S, Nakazono K, Murasawa A, Nishida K, Ozaki T. Risk factors of postoperative delayed wound healing in patients with rheumatoid arthritis treated with a biological agent. *Mod Rhematol* DOI: 10.1080/14397595.2020.1790138
18. Ito S. Updates on management strategies of hepatitis B virus reactivation in patients with resolved hepatitis virus B infection undergoing immunosuppressive therapy in rheumatology and the current situation in Niigata Rheumatic Center. *Mod Rheumatol* DOI: 10.1080/14397595.2020.1832731
19. Kobayashi D, Hasegawa E, Ito S, Abe A, Otani H, Ishikawa H, Murasawa A, Nakazono K, Narita I, Amao S. Joint overuse in rheumatois arthritis patients. *Clinical Rheumatol Rel Res* 32:201-209, 2020
20. Nemoto T, Ito S, Kobayashi D, Takai C, Sakai S, Kurosawa Y, Hasegawa E, Okabayashi R, Abe A, Otani H, Lee H, Murasawa A, Narita I, Nakazono K, Toyoshima Y, Inagaki K, Ishikawa H. Long-term use of golimumab in daily practice for patients with rheumatoid arthritis. *Intern Med* DOI: 10.1080/14397595.2020.1832731

和文

1. 長谷川絵理子、伊藤 聰、小林大介、成田一衛、石川 肇. イグラチモドの腎機能に与える影響. 臨床リウマチ 31(2):145-154, 2019
2. 黒澤陽一、伊藤 聰、坂井俊介、長谷川絵理子、岡林 諒、阿部麻美1、大谷 博、中園 清、村澤 章、成田一衛、石川 肇. レミチェック Q®を使用したインフリキシマブ血中濃度測定の臨床的意義. 臨床リウマチ 32 (1) 13-20, 2020
3. 長谷川絵理子、伊藤 聰、黒澤陽一、小林大介、阿部麻美、大谷 博、中園 清、村澤 章、成田一衛、石川 肇. 高齢発症関節リウマチに対するセルトリズマブペゴル早期治療の有用性. 臨床リウマチ 32:114-122, 2020
4. 黒澤陽一、伊藤 聰、坂井俊介、成田一衛、石川 肇. ゴリムマブ自己注射の実態調査. 中部リウマチ 49:2:14-17, 2019
5. 岡林 諒、石川 肇、大谷 博、伊藤 聰、黒澤陽一、坂井俊介、中園 清、村澤 章. 関節リウマチ患者に対する”フレイル入院”の導入. 中部リウマチ 49:2:18-22, 2019
6. 菊地珠美、黒田 育、伊藤 聰 超高齢者を含む高齢RA患者に対するバリシチニブ投与経験 新薬と臨牀 69:591-598, 2020
7. 坂井俊介、伊藤 聰、黒澤陽一、岡林 諒、阿部麻美、大谷 博、中園 清、村澤 章、成田一衛、石川 肇 当院関節リウマチ患者におけるヤヌスキナーゼ阻害薬の使用経験 新潟県病医誌 68:24-28, 2020
8. 黒澤陽一、伊藤 聰、坂井俊介、成田一衛、石川 肇 リウマチ・膠原病患者におけるエソメプラゾール処方実態の検討 中部リウマチ 50(1) 3-8, 2020
9. 伊藤 聰、佐藤弘恵、成田一衛、石川 肇、中園 清 関節リウマチ患者における血清 25(OH)ビタミンD濃度についての検討 新薬と臨牀 69: 1176-1188, 2020

症例報告 :

1. 伊藤 聰 小林泰輔、野口英雄、石井義則 イグラチモド内服中止後も肝機能障害が進行し、遷延した関節リウマチの一例 新薬と臨牀 69: 865-872, 2020